The Manufacturers Life Insurance Company Takes $79,000 Position in Compass Therapeutics, Inc. (NASDAQ:CMPX)

The Manufacturers Life Insurance Company purchased a new stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 42,671 shares of the company’s stock, valued at approximately $79,000.

Other institutional investors have also recently bought and sold shares of the company. Rovin Capital UT ADV bought a new position in Compass Therapeutics in the 3rd quarter valued at $25,000. Intech Investment Management LLC acquired a new position in shares of Compass Therapeutics during the third quarter valued at $30,000. SG Americas Securities LLC boosted its holdings in Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after acquiring an additional 5,515 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Compass Therapeutics in the second quarter worth about $41,000. Finally, Panagora Asset Management Inc. acquired a new stake in Compass Therapeutics in the second quarter worth about $68,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

Shares of NASDAQ:CMPX opened at $1.53 on Wednesday. The firm’s 50 day simple moving average is $1.67 and its 200 day simple moving average is $1.41. Compass Therapeutics, Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $2.34. The company has a market capitalization of $210.51 million, a price-to-earnings ratio of -4.14 and a beta of 0.89.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. Equities research analysts expect that Compass Therapeutics, Inc. will post -0.35 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Monday, November 11th. Leerink Partnrs cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $5.00 to $4.00 in a research report on Friday, November 15th. Finally, LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $6.75.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.